Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi Therapeutic

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/20/2017 | 02:57pm CEST
   By Sonia Amaral Rohter 
 

Sanofi SA (>> Sanofi) and Alnylam Pharmaceuticals Inc. (>> Alnylam Pharmaceuticals, Inc.) reported Wednesday that Patisiran met all primary and secondary endpoints in a Phase III trial of its use against a rare, inherited disorder.

The trial looked at the use of Patisiran in patients with hereditary transthyretin-mediated amyloidosis, a progressively debilitating disease in which a gene mutation causes the production of a type of abnormal protein that accumulates in body organs and tissues, damaging them. Patisiran is designed to target and silence the mechanism that leads to production of this protein.

Patisiran is part of a class of medicines called RNA interference, or RNAi, therapeutics that aim to inhibit the expression of certain genes in order to treat or prevent disease.

Alnylam Chief Executive John Maraganore said: "We are very proud to report the first-ever positive Phase III results for an RNAi therapeutic, marking the potential arrival of an entirely new class of medicines."

Alnylam said it would file a new drug application with the U.S. Food and Drug Administration in late 2017. Should the company receive regulatory approval, Alnylam will commercialize Patisiran in the U.S., Canada and Western Europe, while Sanofi Genzyme will commercialize the product in the rest of the world.

The full results of the trial will be presented on November 2.

Write to Sonia Amaral Rohter at [email protected]

Stocks mentioned in the article : Sanofi, Alnylam Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
02:02p SANOFI : and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in ..
09:28a SANOFI : invests EUR170 million in new vaccine production facility in France
10/13 HISTOGENICS CORPORATION : Promotes Stephen Kennedy to Executive Vice President &..
10/13 SANOFI : Invests EUR 170 Million in New Vaccine Production Facility in France
10/13 SANOFI : invests 170 million in vaccine production facility in France
10/13 SANOFI : to invest 170 million in new vaccine production facility in France
10/13 SANOFI : set for 170 million expansion of vaccine facility
10/13 SANOFI : - Internationally Acclaimed Writer and Executive Producer of HBO's The ..
10/12 SANOFI : New Findings from Sanofi Pasteur Update Understanding of Vaccines (Inco..
10/12 SANOFI : Availability of the Pre-quarterly Results Communication
More news
News from SeekingAlpha
12:54p MANNKIND CORPORATION : Can Afrezza Improved Labeling Fuel A Successful Comeback?
12:06p Regeneron and Sanofi's Dupixent shows treatment effect in mid-stage eosinophi..
11:21a SANOFI : Upward Trajectory In 2017
10/12 Sanofi to invest ?170M to expand France vaccine manufacturing site
10/10 YOUR DAILY PHARMA SCOOP : MannKind Is A Trade Not An Investment; AstraZeneca's I..
Financials (€)
Sales 2017 36 216 M
EBIT 2017 9 611 M
Net income 2017 8 042 M
Debt 2017 5 004 M
Yield 2017 3,62%
P/E ratio 2017 12,94
P/E ratio 2018 17,37
EV / Sales 2017 3,05x
EV / Sales 2018 2,97x
Capitalization 106 B
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 86,9 €
Spread / Average Target 3,9%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI8.71%124 781
JOHNSON & JOHNSON18.42%366 178
NOVARTIS13.23%225 160
ROCHE HOLDING LTD.5.20%216 764
PFIZER11.88%216 409
MERCK AND COMPANY7.68%172 887